Description
Semaglutide is a synthetic analogue of the human incretin hormone GLP-1 (7-37), maintaining 94% structural homology. To overcome the rapid degradation of native GLP-1 (which has a half-life of roughly 2 minutes), three strategic modifications were made:
- Position 8 (Ala → Aib): The substitution of Alanine with alpha-aminoisobutyric acid (Aib) renders the peptide resistant to enzymatic cleavage by dipeptidyl peptidase-4 (DPP-4).
- Position 26 (Lys acylation): The Lysine at position 26 is acylated with a C-18 fatty diacid chain via a gamma-Glu-2xOEG spacer. This allows the molecule to bind reversibly to serum albumin, significantly slowing renal clearance.
- Position 34 (Lys → Arg): Lysine is replaced with Arginine to ensure the fatty acid chain attaches specifically to position 26 and prevents incorrect acylation.
Pharmacodynamics & Mechanism (MOA)
Semaglutide acts as a selective GLP-1 receptor agonist (GLP-1RA). It binds to the GLP-1 receptor, a Class B G-protein-coupled receptor (GPCR), initiating an intracellular signaling cascade:
- Adenylate Cyclase Activation: Receptor binding activates G-proteins, stimulating adenylate cyclase and increasing intracellular cyclic AMP (cAMP).
- Pancreatic Regulation: In the beta-cells, elevated cAMP triggers the release of insulin in a glucose-dependent manner (meaning it only acts when blood sugar is elevated). Simultaneously, it suppresses glucagon secretion from alpha-cells.
- Gastric Emptying: It attenuates postprandial glucose spikes by delaying gastric motility.
- Neuroendocrine Signaling: It crosses the blood-brain barrier to target the arcuate nucleus of the hypothalamus, modulating pro-opiomelanocortin (POMC) and neuropeptide Y (NPY) neurons to decrease appetite and increase satiety.
Pharmacokinetics (PK)
The molecular modifications result in a highly stable pharmacokinetic profile, allowing for a weekly dosing interval rather than the daily requirements of earlier GLP-1 analogs.
| Parameter | Clinical Value |
| Bioavailability (SC) | Approximately 89% |
| Peak Concentration | 1 to 3 days post-administration |
| Elimination Half-life | Approximately 165–184 hours (~7 days) |
| Metabolism | Proteolytic cleavage of the peptide backbone and $\beta$-oxidation of the fatty acid side chain |
| Excretion | Primarily renal and fecal (as metabolites) |
4. Clinical Implications
Due to its systemic reach, Semaglutide offers more than just glycemic control. Research in the STEP (weight management) and SUSTAIN (diabetes) trials demonstrated:
- Cardiovascular Protection: Reductions in major adverse cardiovascular events (MACE) by lowering systemic inflammation and improving lipid profiles.
- Neuroprotection: Potential therapeutic benefit in reducing neuroinflammation, which is currently being studied for Alzheimer’s and Parkinson’s disease.
